Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Dana Farber and 454 life sciences announce breakthrough in DNA sequencing for cancer research

27.06.2006
Sequencing method detects cancer mutations at the molecular level
454 Life Sciences Corporation, a majority-owned subsidiary of CuraGen Corporation (Nasdaq: CRGN), in collaboration with scientists at Dana Farber Cancer Center and Broad Institute, today reported a new method for the detection of cancer gene mutations present at extremely low levels. The research, published online (ahead of print) in the journal Nature Medicine, describes how the 454 SequencingTM method identifies rare cancer-associated genetic variations at the molecular level, potentially enabling the personalization of targeted therapies.

454 SequencingTM technology was used to analyze mutations in five exons of the Epidermal Growth Factor Receptor (EGFR) gene in tumor samples from 22 patients with lung cancer. The EGFR gene is the target for several new anti-cancer drugs called EGFR inhibitors. This research proposes that 454 SequencingTM may help to validate the ability of EGFR mutations to predict patient responsiveness to treatment with an EGFR inhibitor.

It has been realized that genetic mutations are responsible for sensitizing some tumor cells to chemotherapy, while other mutations render tumor cells completely resistant to drug treatments. Historically, research progress has been slowed by the complex mix of cells in a tumor sample, compounded by cost-prohibitive, conventional low-resolution sequencing methods that lack sufficient accuracy to characterize the DNA in cancerous cells. 454 SequencingTM is the first advanced sequencing technology that can generate hundreds of thousands of DNA sequences in one run, rapidly and comprehensively conducting high-throughput nucleotide sequencing, with specific application to sequencing of whole genomes and ultra-deep sequencing of target genes. By enabling a method of sequencing that is more comprehensive and less expensive than conventional sequencing methods, 454 SequencingTM may be used in medical research settings to detect cancer-associated genetic mutations.

"Analysis of DNA from tumors is complicated by varying amounts of tumor cells in patient samples. Furthermore, the heterogeneous nature of many tumors makes it difficult to accurately sequence the tumor DNA, which is required in order to personalize treatment," explained senior author of the study, Matthew Meyerson, M.D. Ph.D., of Dana Farber Cancer Center and Broad Institute. "454 Sequencing may facilitate accurate molecular diagnosis of heterogeneous cancer specimens and enable patient selection for targeted cancer therapies," added Meyerson.

The technology is already being explored at other institutions. "We have validated 454 Sequencing for medical sequencing on a gene target of interest," stated Robert Strausberg, Ph.D. Deputy Director and Vice President of Human Genomic Medicine at The J. Craig Venter Institute. "The method is not only very sensitive, but it is also quantitative and provides a digital display of gene variation within tumors. We have already identified a mutation missed by our previous sequencing approach," said Strausberg.

"The publication of this paper demonstrates the versatility of our system and its ability to enable medical research that has been considered impractical until now," stated co-author Michael Egholm, Ph.D., Vice President of Molecular Biology at 454 Life Sciences. "454 Sequencing can open new research opportunities through its low cost, high throughput, and superior sensitivity. The ability to sequence entire exons in a single read is unique to 454 Sequencing among the commercially available, next generation sequencing technologies. Ultimately, we hope our system will enable personalized medicine, such as identifying the early stages of drug resistance and facilitating a change in treatment that is tailored to a patient's unique genetic response," added Egholm.

About 454 Life Sciences

454 Life Sciences, a 66% majority-owned subsidiary of CuraGen Corporation (Nasdaq: CRGN), is commercializing novel instrumentation and measurement services for rapidly and comprehensively conducting high-throughput nucleotide sequencing, with specific application to sequencing of whole genomes and ultra-deep sequencing of target genes. 454 Life Sciences' Genome Sequencer 20 System enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. The hallmark of 454 Life Sciences' technology is the PicoTiterPlate, which allows a single instrument using patented light emitting sequencing chemistries to produce over 20 million nucleotide bases per five-hour run, totaling more than 60 times the capacity of instruments using the current macro-scale technology.

For additional information on 454 Life Sciences, please visit http://www.454.com. For additional information on the Genome Sequencer 20 System and reagents, please visit http://www.roche-applied-science.com.

Safe Harbor

This press release contains forward-looking statements that are subject to certain risks and uncertainties. These statements include statements that 454 SequencingTM (i) may validate the power of EGFR mutations to predict patient responsiveness to treatment with an EGFR inhibitor, (ii) may be used in medical research settings to detect cancer-associated genetic mutations, (iii) may facilitate accurate molecular diagnosis of heterogeneous cancer specimens and enable patient selection for targeted cancer therapies, (iv) may enable medical research that has been considered impractical until now through its low cost, high throughput, and superior sensitivity, and (v) may enable personalized medicine, such as identifying the early stages of drug resistance and facilitating a change in treatment that is tailored to a patient's unique genetic response. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. 454 Life Sciences and CuraGen caution investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of development of 454 Life Sciences' products and technologies; customer acceptance of 454 Life Sciences' products and technologies; 454 Life Sciences' ability to scale-up production of its products and technologies; disputes between 454 Life Sciences and CuraGen; the success of competing products and technologies; technological uncertainty and product development risks; uncertainties of clinical trials, government regulation and healthcare reform; uncertainty of additional funding with respect to both CuraGen and 454 Life Sciences; 454 Life Sciences' and CuraGen's history of incurring losses and the uncertainty of achieving profitability; CuraGen's stage of development as a biopharmaceutical company; patent infringement claims against 454 Life Sciences' and CuraGen's products, processes and technologies; the ability to protect 454 Life Sciences' and CuraGen's patents and proprietary rights; uncertainties relating to commercialization rights; product liability exposure; and competition. Please refer to CuraGen's Annual and Quarterly Reports on Forms 10-K and 10-Q for a complete description of these risks. 454 Life Sciences and CuraGen disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

454® is a registered trademark of 454 Life Sciences Corporation. 454 Life SciencesTM, Genome Sequencer 20TM, PicoTiterPlateTM, and 454 SequencingTM are trademarks of 454 Life Sciences Corporation.

Benjamin Carmichael | EurekAlert!
Further information:
http://www.454.com
http://www.roche-applied-science.com

More articles from Life Sciences:

nachricht Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory

nachricht Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>